CompletedPhase 2NCT04184063

Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)

Studying Classic progressive supranuclear palsy syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
EmeraMed
Principal Investigator
Tanja Turk, M. Pharm
CRS d.o.o.
Intervention
NBMI(drug)
Enrollment
20 enrolled
Eligibility
40-85 years · All sexes
Timeline
20192021

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04184063 on ClinicalTrials.gov

Other trials for Classic progressive supranuclear palsy syndrome

Additional recruiting or active studies for the same condition.

See all trials for Classic progressive supranuclear palsy syndrome

← Back to all trials